Humana (NYSE:HUM) Raised to “Neutral” at Bank of America

Humana (NYSE:HUM) was upgraded by investment analysts at Bank of America from an “underperform” rating to a “neutral” rating in a research note issued on Wednesday, MarketBeat Ratings reports. The firm currently has a $308.00 price target on the insurance provider’s stock, up from their previous price target of $247.00. Bank of America‘s price objective would suggest a potential upside of 7.03% from the stock’s current price.

Other analysts also recently issued reports about the stock. Leerink Partners downgraded shares of Humana from an “outperform” rating to a “market perform” rating and cut their target price for the company from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Leerink Partnrs downgraded Humana from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Deutsche Bank Aktiengesellschaft dropped their target price on Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a report on Thursday, October 3rd. JPMorgan Chase & Co. raised their price target on shares of Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a report on Wednesday, August 21st. Finally, Barclays upped their price objective on shares of Humana from $250.00 to $253.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Twenty equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $315.86.

Humana Trading Down 0.3 %

NYSE:HUM opened at $287.76 on Wednesday. The stock has a fifty day simple moving average of $291.98 and a 200 day simple moving average of $333.24. The firm has a market capitalization of $34.65 billion, a price-to-earnings ratio of 25.56, a price-to-earnings-growth ratio of 1.98 and a beta of 0.52. Humana has a 1-year low of $213.31 and a 1-year high of $527.18. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping the consensus estimate of $3.48 by $0.68. The company had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. Sell-side analysts forecast that Humana will post 16.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HUM. Swedbank AB grew its holdings in shares of Humana by 3.0% during the 3rd quarter. Swedbank AB now owns 105,976 shares of the insurance provider’s stock worth $33,567,000 after purchasing an additional 3,085 shares in the last quarter. Heritage Oak Wealth Advisors LLC acquired a new position in shares of Humana in the 2nd quarter valued at $3,456,000. Mandatum Life Insurance Co Ltd boosted its position in shares of Humana by 115.4% during the 3rd quarter. Mandatum Life Insurance Co Ltd now owns 14,000 shares of the insurance provider’s stock valued at $4,434,000 after acquiring an additional 7,500 shares in the last quarter. APG Asset Management US Inc. boosted its position in shares of Humana by 3.0% during the 2nd quarter. APG Asset Management US Inc. now owns 67,669 shares of the insurance provider’s stock valued at $25,274,000 after acquiring an additional 1,955 shares in the last quarter. Finally, Sei Investments Co. increased its stake in Humana by 0.4% in the first quarter. Sei Investments Co. now owns 61,897 shares of the insurance provider’s stock valued at $21,462,000 after acquiring an additional 264 shares during the period. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.